Skip to content

Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.

Efficacy of Nasojejunal Enteral Feeding in Critically Ill Patients.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00256048
Enrollment
50
Registered
2005-11-21
Start date
2003-05-31
Completion date
2005-07-31
Last updated
2017-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically Ill

Brief summary

The purpose of this study is to determine if naso-jejunal feeding (feeding beyond the stomach) improves the efficacy of enteral feeding (feeding into the gut) in critically ill patients. The study hypothesis is that in patients who fail to establish enteral feeding via the nasogastric route, introduction of nasojejunal feeding will lead to more effective enteral feeding than the current regime involving staged introduction of promotility agents.

Detailed description

The study examines the area of enteral feeding in critically ill patients. Current standard enteral feeding practice is via a nasogastric with the addition of promotility agents for patients who fail to absorb their enteral nutrition. This study compares the efficacy of nasojejunal feeding feeding with nasogastric enteral feeding with the addition of promotility agents. The duration of feeding will be determined by the patients nutritional requirements and their general condition. However the data will be collected for duration of enteral feeding, 28 days or ICU discharge whichever occurs first.

Interventions

PROCEDURENasojejunal feeding

Sponsors

Melbourne Health
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult patients (18years or over) admitted to the ICU with an expected stay of more than 48 hours. 2. Patients commenced on enteral feeding via a nasogastric tube who fail to tolerate gastric feeding due to excessive gastric aspirate volumes. 3. Patients who consent or if the patient is incompetent, the next of kin, who consent, to inclusion in the study. \-

Exclusion criteria

1. patients less than 18 years of age. 2. Patients with known allergy to promotility agents, metoclopramide or erythromycin. 3. Patients with a contra indication to nasojejunal feeding. -

Design outcomes

Primary

MeasureTime frame
Efficacy of feedingparticipants will be followed until death, discharge from ICU, commencement of oral or parental nutrition or 28 days post ICU admission

Secondary

MeasureTime frame
1. To determine the incidence of complications with enteral feeding via nasogastric and nasojejunal routes.participants will be followed until death, discharge from ICU, commencement of parental or oral nutrition or 28 days post ICU admission.
2. To assess the efficacy of current strategies for optimising enteral feeding efficacy.participants will be followed until death, discharge from ICU commencement of oral or parental nutrition,or 28 days post ICU admission.

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026